Paper Details

  1. Home
  2. Paper Details

A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.

Author: BlumenfeldAndrew M, CadyRoger K, FarmerKathleen U, PorterJohn A H, SchreiberCurtis P

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the effectiveness of onabotulinumtoxinA and topiramate in treating chronic migraine. Both treatments were shown to be beneficial in reducing headache frequency, but there was no significant difference between the two groups. By week 26, subjects in both groups had a reduction in headache days per month compared to baseline.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: This multi-center pilot study compared the efficacy of onabotulinumtoxinA with topiramate (a Food and Drug Administration approved and widely accepted treatment for prevention of migraine) in individuals with chronic migraine (CM). METHODS: A total of 59 subjects with CM were randomly as...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1526-4610.2010.01796.x

データ提供：米国国立医学図書館（NLM）

OnabotulinumtoxinA vs. Topiramate: A Head-to-Head Comparison for Chronic Migraine

Chronic migraine (CM) is a debilitating condition that can significantly impact an individual's quality of life. This study explores the efficacy of onabotulinumtoxinA, a botulinum toxin injection, in comparison to topiramate, a widely accepted medication for migraine prevention, in managing CM. The researchers conducted a multi-center pilot study to compare the effectiveness of these two treatments.

OnabotulinumtoxinA and Topiramate: Similar Efficacy for Chronic Migraine

The study revealed that both onabotulinumtoxinA and topiramate demonstrated positive benefits in reducing headache days and improving overall migraine severity in patients with CM. While statistical significance was observed within each treatment group, there was no significant difference between the groups, suggesting comparable efficacy. These findings indicate that both onabotulinumtoxinA and topiramate can be valuable options for managing CM.

Navigating the Desert of Chronic Migraine: Finding Relief

Imagine CM as a relentless desert sandstorm, with frequent and debilitating headaches. OnabotulinumtoxinA and topiramate, like protective shields, can help to reduce the intensity and frequency of these storms. The study suggests that both treatments offer comparable relief for patients, giving them a choice in navigating the desert of chronic migraine.

Dr.Camel's Conclusion

This study provides valuable insights into the efficacy of both onabotulinumtoxinA and topiramate for managing chronic migraine. The comparable effectiveness of these treatments offers patients more options in navigating the challenges of this debilitating condition.

Date :
  1. Date Completed 2011-04-25
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

21070228

DOI: Digital Object Identifier

10.1111/j.1526-4610.2010.01796.x

Related Literature

Article Analysis
・Effective treatment of migraine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.